Soligenix (SNGX)

Executive Summary

Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing therapies for rare diseases, with key programs in oncology and inflammation. Its lead asset, SGX301 (synthetic hypericin), is a novel photodynamic therapy for cutaneous T-cell lymphoma (CTCL), having completed a Phase 3 trial (NCT02448381) and now enrolling a confirmatory Phase 3 trial (NCT06470451) expected to complete in October 2026. Other notable programs include SGX942 for oral mucositis (Phase 3 completed) and a ricin toxin vaccine in collaboration with the University of Hawaiʻi. The company’s pipeline also comprises multiple early-stage candidates, but near-term value is heavily dependent on the success of hypericin in CTCL.

Upcoming Catalysts (preview)

• Q4 2026Phase 3 Top-Line Data for Hypericin in CTCL (NCT06470451)60% success
• Q1 2027Potential FDA Meeting or NDA Submission for SGX30140% success
• Q2 2026Phase 2 Data for Hypericin + Mechlorethamine Topical Gel in CTCL50% success